Epidermal growth factor (EGF)-induced EGFR tyrosine kinase receptor activation in cancer
cell survival responses has become a strategic molecular-targeting clinical therapeutic …

This study aimed to develop rational combinations of targeted agents against biliary and
pancreatic cancers. To this end, we compared the global gene expression profile of biliary …

The insulin-like growth factor (IGF) signaling system plays a crucial role in human cancer
and the IGF-1 receptor (IGF-1R) is an attractive drug target against which a variety of novel …

To test the hypothesis that concomitant targeting of the epidermal growth factor receptor
(EGFR) and transforming growth factor-beta (TGF-β) may offer a novel therapeutic approach …

Pancreatic cancer is one of the most lethal cancers. Increasing incidence and mortality
indicates that there is still much lacking in detection and management of the disease. This is …

Purpose: We previously established a mechanistic rationale for Src inhibition as a novel
therapeutic target in pancreatic cancer and have identified activated STAT3 as a potential …

Background The insulin-like growth factor (IGF) axis is an important signaling pathway in the
growth and survival of many cell and tissue types. This pathway has also been implicated in …

Purpose: The combination of erlotinib and gemcitabine has shown a small but statistically
significant survival advantage when compared with gemcitabine alone in patients with …

It is believed that the insulin-like growth factor receptor type 1 (IGF-1R) signaling pathway
plays a pivotal role in cancer growth, progression, and resistance to anticancer therapies …

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is
one of the most lethal human diseases. PDAC is now the fourth leading cause of cancer …